Skip to main content
رجوع
Watch Compare

Pasithea Therapeutics Corp.

جودة البيانات: 83%
مُدرج أيضًا باسم KTTAW Nasdaq
KTTA
Nasdaq Manufacturing Chemicals
KWD 0.74
▼ KWD 0.03 (-3.39%)
القيمة السوقية: 18.46 M
السعر
KWD 0.74
القيمة السوقية
18.46 M
نطاق اليوم
KWD 0.70 — KWD 0.78
نطاق 52 أسبوعًا
KWD 0.28 — KWD 3.79
حجم التداول
2,580,287
فتح KWD 0.73
متوسط 50 يوم / 200 يوم
KWD 0.80
7.23% below
متوسط 50 يوم / 200 يوم
KWD 0.81
8.78% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -15.21 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-149.19%
أقل من متوسط القطاع (-53.47%)
ROIC-119.72%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio4.02
Interest CoverageN/A

التقييم

PE (TTM)
-0.90
أعلى من متوسط القطاع (-1.47)
P/B Ratio1.51
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -0.9 -1.5
P/B 1.5 1.6
ROE % -149.2 -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

PSIL logo PSIL AdvisorShares Psychedelics ETF
1.08% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -20.43 M
ROE -149.19% ROA -133.34%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -15.21 M
ROIC -119.72% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.02
Interest Coverage N/A Asset Turnover N/A
Working Capital 4.15 M Tangible Book Value 4.11 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.90 Forward P/E N/A
P/B Ratio 1.51 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -82.41%
Market Cap 18.46 M Enterprise Value 14.34 M
Per Share
EPS (Diluted TTM) -2.91 Revenue / Share N/A
FCF / Share -0.61 OCF / Share -0.61
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 74.47%
SBC-Adj. FCF -15.57 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — 486,559.0 15,062.0
Net Income -20.43 M -13.90 M -15.96 M -13.94 M -2.17 M
EPS (Diluted) -2.91 -0.42 -0.42 -0.53 —
Gross Profit — — — — -2,213.0
Operating Income -20.86 M -14.25 M -15.98 M -14.82 M -4.51 M
EBITDA — — — — —
R&D Expenses 7.98 M 7.20 M 8.10 M 2.67 M —
SG&A Expenses — 7.05 M 7.88 M 12.52 M 4.51 M
D&A — — — — —
Interest Expense — — — 102.0 -508.0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 60.24 M 16.06 M 26.12 M 45.18 M 53.32 M
Total Liabilities 5.02 M 1.28 M 2.72 M 2.68 M 1.90 M
Shareholders' Equity 55.22 M 14.78 M 23.40 M 42.50 M 51.42 M
Total Debt — — — — —
Cash & Equivalents 55.16 M 6.92 M 16.33 M 33.15 M 52.97 M
Current Assets 56.46 M 7.37 M 16.69 M 34.08 M 53.30 M
Current Liabilities 4.97 M 1.12 M 2.63 M 1.88 M 447,280.0